SELLAS Life Sciences Announces $150 Million Public Offering of Common Stock
SELLAS Life Sciences Group (SLS) has officially commenced an underwritten public offering of its common stock, aiming to raise approximately $150 million. The company has also granted underwriters a 30-day option to purchase up to an additional $22.5 million in shares. This capital raise is intended to bolster the company's liquidity and support ongoing operations. Such offerings are typical for biotechnology firms requiring significant funding for clinical development, though they often result in short-term share dilution for existing investors.

Tickers: $SLS
Topics: Capital Raising Common Stock Public Offering
Read the full article at Seeking Alpha
Part of the story SELLAS Life Sciences Group, Inc. - 8-K Filing (3 articles)